Amgen: The Defensive Anchor in the Biotech Sector
Amgen demonstrates enormous operational strength through its recent record figures, making the company, thanks to crisis-resistant cash flows and a well-stocked pipeline, the ideal defensive core investment in the biotech sector.
Reading Time: 2 minutes
In the often volatile world of biotechnology, Amgen (i) has established itself as a rare constant, offering long-term oriented investors an ideal mix of stability and growth. The recent quarterly figures from February 3, 2026, impressively underline this status: with a revenue increase of 9% to nearly $10 billion and a significant profit surge, the company not only met but exceeded market expectations. Particularly, the integration of strategic acquisitions like Horizon Therapeutics is now yielding visible results and diversifying the portfolio...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
